Martin B. Gill, PhD
Director, Head of In Vitro Pharmacology at Neuropore Therapies, Inc.
Location: San Diego, California, United States
Dr. Gill received his doctorate in Neuroscience from the University of Texas-Medical Branch investigating neurodegenerative apoptotic/necroptotic signaling. He conducted post-doctoral work at Northwestern University, Feinberg School of Medicine, investigating glutamate receptor biogenesis/electrophysiology, in addition to identifying/evaluating novel, marine-based pharmacophores which could modulate neuronal function.
In 2009, Dr. Gill joined Eli Lilly and Company as a member of Neuroscience Discovery team supporting target identification/validation and lead optimization efforts. In 2011, he joined the Genetically-Defined Disease division at Bristol-Myers Squibb where he managed a senior scientific team focused on in vitro/in vivo assay development to support portfolio program progression. In addition, he served as biology co-chair for internal small molecule and antisense programs, as well as managed the biological evaluation of in-licensing asset opportunities.
Dr. Gill joined the Neuropore Therapies team in 2016 where he manages the in vitro discovery efforts to identify, validate and optimize novel small molecule therapeutic assets for inflammation-/autophagy-based targets.